In July 2019, the FDA approved darolutamide (Nubeqa, Bayer) for men with prostate cancer that has not spread (ie, nonmetastatic) and no longer responds to medical or surgical treatment that lowers testosterone (ie androgen deprivation therapy).
Cedric White, PharmD candidate 2020, and Lisa M. Holle, PharmD, BCOP, FHOPA, FISOPP
Advertisement
Articles by Cedric White, PharmD candidate 2020, and Lisa M. Holle, PharmD, BCOP, FHOPA, FISOPP
Advertisement
Latest Updated Articles
Darolutamide for Non-Metastatic Castration-Resistant Prostate CancerPublished: May 11th 2020 | Updated:
Advertisement
Advertisement
Trending on Drug Topics
1
FDA Approves Enflonsia for the Prevention of RSV Lower Respiratory Tract Disease in Infants
2
How Pharmacies’ Ability to Provide Behavioral Health Services is Growing | NCPA 2025
3
Pharmacists Experience Challenges in Credentialing, Billing for Services | NCPA 2025
4
American Pharmacists Month: How Pharmacy Partnerships Create Pathway to Innovation
5
